Cargando…

Natural Killer Cell-Based Immunotherapy against Glioblastoma

Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS) after diagnosis is approximately 2 years and the 5-year OS...

Descripción completa

Detalles Bibliográficos
Autores principales: Morimoto, Takayuki, Nakazawa, Tsutomu, Maeoka, Ryosuke, Nakagawa, Ichiro, Tsujimura, Takahiro, Matsuda, Ryosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916747/
https://www.ncbi.nlm.nih.gov/pubmed/36768432
http://dx.doi.org/10.3390/ijms24032111
_version_ 1784886200824233984
author Morimoto, Takayuki
Nakazawa, Tsutomu
Maeoka, Ryosuke
Nakagawa, Ichiro
Tsujimura, Takahiro
Matsuda, Ryosuke
author_facet Morimoto, Takayuki
Nakazawa, Tsutomu
Maeoka, Ryosuke
Nakagawa, Ichiro
Tsujimura, Takahiro
Matsuda, Ryosuke
author_sort Morimoto, Takayuki
collection PubMed
description Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS) after diagnosis is approximately 2 years and the 5-year OS is poor. Considering the poor prognosis, novel treatment strategies are needed, such as immunotherapies, which include chimeric antigen receptor T-cell therapy, immune checkpoint inhibitors, vaccine therapy, and oncolytic virus therapy. However, these therapies have not achieved satisfactory outcomes. One reason for this is that these therapies are mainly based on activating T cells and controlling GBM progression. Natural killer (NK) cell-based immunotherapy involves the new feature of recognizing GBM via differing mechanisms from that of T cell-based immunotherapy. In this review, we focused on NK cell-based immunotherapy as a novel GBM treatment strategy.
format Online
Article
Text
id pubmed-9916747
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99167472023-02-11 Natural Killer Cell-Based Immunotherapy against Glioblastoma Morimoto, Takayuki Nakazawa, Tsutomu Maeoka, Ryosuke Nakagawa, Ichiro Tsujimura, Takahiro Matsuda, Ryosuke Int J Mol Sci Review Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS) after diagnosis is approximately 2 years and the 5-year OS is poor. Considering the poor prognosis, novel treatment strategies are needed, such as immunotherapies, which include chimeric antigen receptor T-cell therapy, immune checkpoint inhibitors, vaccine therapy, and oncolytic virus therapy. However, these therapies have not achieved satisfactory outcomes. One reason for this is that these therapies are mainly based on activating T cells and controlling GBM progression. Natural killer (NK) cell-based immunotherapy involves the new feature of recognizing GBM via differing mechanisms from that of T cell-based immunotherapy. In this review, we focused on NK cell-based immunotherapy as a novel GBM treatment strategy. MDPI 2023-01-20 /pmc/articles/PMC9916747/ /pubmed/36768432 http://dx.doi.org/10.3390/ijms24032111 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Morimoto, Takayuki
Nakazawa, Tsutomu
Maeoka, Ryosuke
Nakagawa, Ichiro
Tsujimura, Takahiro
Matsuda, Ryosuke
Natural Killer Cell-Based Immunotherapy against Glioblastoma
title Natural Killer Cell-Based Immunotherapy against Glioblastoma
title_full Natural Killer Cell-Based Immunotherapy against Glioblastoma
title_fullStr Natural Killer Cell-Based Immunotherapy against Glioblastoma
title_full_unstemmed Natural Killer Cell-Based Immunotherapy against Glioblastoma
title_short Natural Killer Cell-Based Immunotherapy against Glioblastoma
title_sort natural killer cell-based immunotherapy against glioblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916747/
https://www.ncbi.nlm.nih.gov/pubmed/36768432
http://dx.doi.org/10.3390/ijms24032111
work_keys_str_mv AT morimototakayuki naturalkillercellbasedimmunotherapyagainstglioblastoma
AT nakazawatsutomu naturalkillercellbasedimmunotherapyagainstglioblastoma
AT maeokaryosuke naturalkillercellbasedimmunotherapyagainstglioblastoma
AT nakagawaichiro naturalkillercellbasedimmunotherapyagainstglioblastoma
AT tsujimuratakahiro naturalkillercellbasedimmunotherapyagainstglioblastoma
AT matsudaryosuke naturalkillercellbasedimmunotherapyagainstglioblastoma